| Galectin-1 supports the survival of CD45RA()) primary myeloma cells in vitro
Summary
The survival and proliferation of human myeloma cells are considered to be
heavily dependent on the microenvironment of bone marrow (BM). This
study confirmed that galectin-1 (Gal-1) and SDF-1a were produced by bone
marrow mononuclear cells of myeloma patients. The addition of Gal-1 and
SDF-1a to a serum-free synthetic medium, maintained the viability of
primary myeloma cells for 2 weeks similar to that before culture. While Gal-1
reduced the viable cell number in CD45RA(+) B cell lines, it maintained the
viability of CD45()) U266 and CD45RA())RO(+) ILKM3 myeloma cell lines
in the synthetic medium. This was confirmed with the transfection of the
PTPRC (CD45) RA, -RB, or -RO gene into CD45()) U266 cells. The
combination of Gal-1 and SDF-1a significantly induced phosphorylation of
Akt and IkB, while the phosphorylation of ERK1/2 was significantly reduced
in CD45RA(+) U266 and Raji cells but not CD45()) or CD45RA()) U266
cells. Furthermore, we confirmed that Gal-1 bound to CD45RA in
CD45RA(+) Raji cells, and also physically interacted with b1-integrin by
immunoprecipitation followed by Western blotting and confocal microscopy.
The results suggest that Gal-1 has two different actions depending on its
binding partner, and supports the survival of CD45RA()) myeloma cells. |